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Abstract
Background: Highly pathogenic avian influenza virus subtype H5N1 infects humans with a high fatality rate and
has pandemic potential. Vaccination is the preferred approach for prevention of H5N1 infection. Seasonal influenza
virus infection has been reported to provide heterosubtypic immunity against influenza A virus infection to some
extend. In this study, we used a mouse model pre-exposed to an H1N1 influenza virus and evaluated the
protective ability provided by a single dose of DNA vaccines encoding conserved H5N1 proteins.
Results: SPF BALB/c mice were intranasally infected with A/PR8 (H1N1) virus beforehand. Six weeks later, the mice
were immunized with plasmid DNA expressing H5N1 virus NP or M1, or with combination of the two plasmids.
Both serum specific Ab titers and IFN-g secretion by spleen cells in vitro were determined. Six weeks after the
vaccination, the mice were challenged with a lethal dose of H5N1 influenza virus. The protective efficacy was
judged by survival rate, body weight loss and residue virus titer in lungs after the challenge. The results showed
that pre-exposure to H1N1 virus could offer mice partial protection against lethal H5N1 challenge and that single-
dose injection with NP DNA or NP + M1 DNAs provided significantly improved protection against lethal H5N1
challenge in mice pre-exposed to H1N1 virus, as compared with those in unexposed mice.
Conclusions: Pre-existing immunity against seasonal influenza viruses is useful in offering protection against H5N1
infection. DNA vaccination may be a quick and effective strategy for persons innaive to influenza A virus during
H5N1 pandemic.
Background
Human infection of highly pathogenic avian H5N1 influ-
enza virus was first reported in Hong Kong in 1997,
causing six deaths [1]. Since then, human cases of
H5N1 virus infection have been continually laboratory-
confirmed in many countries, with approximately 60%
death rate [2]. Probable limited human-to-human spread
of H5N1 subtype virus is believed to have occurred as a
result of prolonged and very close contact [3]. Owing to
the universal lack of pre-existing immunity to H5N1
virus in the population, pandemic caused by the virus
may outbreak. Vaccination is the preferred approach for
the prevention of influenza infection. Inactivated H5N1
influenza vaccines have been proved to be effective in
eliciting neutralizing antibodies against the virus in
clinic trials, but proved to have poor immunogenicity
[4]. Novel strategies, including DNA vaccines, should be
developed to cope with the H5N1 influenza virus that
may cause potential pandemics.
Seasonal influenza A subtypes H1N1 and H3N2 have
globally circulated in humans for a few decades. There
are rare people that have no history of exposure to
these viruses [5,6]. Although it is necessary to annually
update vaccine strains to ensure effective protection
against seasonal influenza infection in humans due to
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human influenza-specific CTLs, mostly targeting con-
served internal proteins, e.g., NP and M1, have been
demonstrated to offer T cell cross-reactivity more or
less against avian influenza H5N1 virus [6-8]. The mem-
ory T cells established by seasonal human influenza A
infection could not provide adequate protection, but
could alleviate symptoms of influenza H5N1 virus infec-
tion [7].
DNA vaccines based on various genes of H5N1
virus have already been explored previously, demon-
strating that, when DNA vaccines encoding NP or M1
were used to immunize mice, multi-dose injection
would be needed to provide effective protection [9].
I nt h i ss t u d y ,as i n g l ed o s eo fv a c c i n a t i o nw i t hN P ,
M1 or NP + M1 DNAs from A/chicken/Henan/12/
2004(H5N1) virus strain was evaluated in mice pre-
exposed to A/PR8(H1N1) virus, which showed that
DNA vaccination might be a quick and effective strat-
egy against H5N1 infection in individuals innaive to
influenza A virus.
Results
Anti-H1N1 antiserum failed to afford protection against
H5N1 in mice
Sera were collected and pooled from mice infected with
A/PR8 (H1N1) influenza virus six weeks before. The
ELISA method was used to detect the anti-H1N1 IgG
Ab titers, while the HI assay to detect HI Ab titers
a g a i n s te i t h e rH 1 N 1o rH 5 N 1i n f l u e n z av i r u s e s .T h e n
24 naive SPF BALB/c mice were passively immunized
with the pooled sera by tail vein injection in a volume
of 300 μl. Twenty-four hours after the serum transfer,
mice were randomized into 2 groups and were chal-
lenged with a lethal dose of H1N1 and H5N1 influenza
viruses, respectively. The results are shown in Table 1.
High Ab titer was detected in mice after infection with
A/PR8 virus. The antiserum contained high HI Ab titer
against H1N1 virus but didn’t contain HI Ab against
H5N1 virus, as proved by the HI assay. All mice receiv-
ing serum transfer survived the lethal challenge with
H1N1 virus, but none survived the lethal H5N1 chal-
lenge. The data indicated that anti-H1N1 Abs were not
able to provide any protection against H5N1 influenza
virus in mice.
Protection against H5N1 influenza virus challenge
One hundred and forty-four SPF BALB/c mice were
randomized into two groups (n = 72). One group was
infected with H1N1 virus, and the other was uninfected.
The subsequent experimental procedure was the same
for the two groups. Six weeks later, mice in each group
were randomly divided into 4 subgroups (n = 18). Three
subgroups were immunized with NP DNA, M1 DNA or
NP + M1 DNAs, respectively, and the rest remained
unimmunized as a control. Six weeks after immuniza-
t i o n ,a l lt h em i c ew e r ec h a l l e n g e dw i t hal e t h a ld o s e
(20LD50) of H5N1 virus. The protective ability of DNA
vaccination was determined by lung virus titer 3 days
post-challenge and body weight change and survival rate
of mice within 21 days.
T h er e s u l t sa r es h o w ni nT a b l e2a n dF i g u r e1 .F o r
uninfected mice, a single dose of NP DNA or NP + M1
DNAs from H5N1 virus provided partial protection
against homologous virus challenge, but M1 DNA
seemed to have no effect, as compared with the unim-
munized control. On the other hand, after infected
beforehand with H1N1 virus, all the mice, including the
unimmunized control, were generally provided with
improved protective ability against lethal H5N1 chal-
lenge, as compared with their respective uninfected cor-
responding. Protection offered by NP DNA or NP + M1
DNAs was significantly better in the infected mice than
in their uninfected corresponding as well as in infected
but unimmunized control. One hundred percent survival
rate was achieved by injection of the infected mice with
NP + M1 DNAs. However, the data derived from M1
DNA vaccination were nearly the same as those from
the unimmunized control in the infected group, as is
the case in uninfected group.
Some conclusions could be drawn from the above
results. Pre-exposure to H1N1 virus enhanced the pro-
tective ability in mice against lethal H5N1 challenge. A
single dose of H5N1 NP DNA or NP + M1 DNAs pro-
vided partial protection against lethal H5N1 virus chal-
lenge in unexposed mice and significantly enhanced
Table 1 Serum Ab titers in mice exposed to A/PR8(H1N1) virus and protection offered by anti-H1N1 antiserum
transfer
§
ELISA Ab (log2)
a HI Ab (log2)
a Survival of passively immunized mice (%)
Anti-H1N1 Anti-H5N1 H1N1 challenge H5N1 challenge
15.3 ± 1.15 7 ± 0* 0 100* 0
§Serum was collected and pooled from mice infected with A/PR8 (H1N1) influenza virus six weeks before. The IgG Ab and HI Ab titers were detected by ELISA
and HI, respectively. Naive BALB/c mice were passively immunized with the pooled serum by tail vein injection in a volume of 300 μl and were then challenged
with a lethal dose (20LD50) of H1N1 or H5N1 influenza virus after 24 hours.
aValues represent means ± SD of each group.
*Significant difference (p < 0.05), compared with the corresponding H5N1 virus group.
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not able to provide effective protection against the virus
challenge in both unexposed and pre-exposed mice.
Ab responses
Mice were grouped and treated as described above.
Three days after the lethal H5N1 challenge, six mice
from each subgroup were taken out for specific IgG Ab
detection, and at the same time, for lung virus titration
as well, as described in the section Methods. The results
are shown in Table 3. For the mice uninfected before-
hand, immunization with NP DNA, M1 DNA or NP +
M1 DNAs induced antigen-specific Abs. When mice
were infected beforehand with H1N1 influenza virus,
both anti-H5 NP and M1 Abs could be detected even in
the unimmunized control mice. Injection with DNA
vaccines significantly increased the specific Abs in mice
pre-exposed to H1N1 virus.
Cell-mediated immunity
Cellular immune responses to DNA vaccines were
assessed by measuring IFN-g secretion in mouse spleno-
cytes. BALB/c mice were randomized into two groups
(n = 24). One group was infected with H1N1 virus and
the other was uninfected. Six weeks later, both groups
were divided into 4 subgroups (n = 6). In both groups,
three of the subgroups were immunized with H5 NP
DNA, M1 DNA or NP + M1 DNAs, respectively, as
described above, and the rest remained unimmunized.
Splenocytes of mice were isolated after 6 weeks and sti-
mulated by the synthesized NP or M1 peptide, as
described in the section Methods. The number of IFN-g
secreting splenocytes was calculated as the average
number of spots in the triplicate stimulant wells. Results
are shown in Figure 2. For mice uninfected beforehand,
H5 NP-specific spots were a little more in mice immu-
nized with NP DNA or NP + M1 DNAs than those in
the unimmunized control, but M1-specific spots could
not be clearly detected in mice immunized with M1
DNA and NP + M1 DNAs. On the other hand, for mice
infected with H1N1 virus beforehand, both H5 NP- and
M1- specific spots could be detected with very low
number in the unimmunized control mice. The H5 NP-
specific spot numbers of mice immunized with NP
DNA and NP + M1 DNAs were significantly increased
compared with those of the unimmunized control, and
were about 5 times and 10 times, respectively, the spot
numbers of the corresponding uninfected but immu-
nized mice. M1-specific spot numbers were about equal
in all immunized mice and the unimmunized control
mice. To sum up, H5 NP-specific splenocytes induced
by NP DNA or NP + M1 DNAs could be greatly
enhanced in mice with pre-existing immunity to H1N1
virus, but H5 M1-specific splenocytes induced by
M1 DNA or NP + M1 DNAs could only be slightly
increased.
Discussion
Seasonal influenza A subtypes H1N1 and H3N2, as well
as type B virus, have globally co-circulated in the
human population for a few decades. Infection of influ-
enza virus induces specific immune responses in the
Table 2 Protection provided by DNA vaccines against lethal homologous H5N1 challenge in mice unexposed and
pre-exposed to H1N1 virus
§
Group Subgroup
(DNA vaccine)
Protection against H5N1 virus challenge (20LD50)
Survival rate
(survival number/total)
Body weight loss (% of the original) Lung virus titers
(log10TCID50/ml)
Unexposed
to H1N1
NP DNA 4/11* 18.4 ± 1.02 9.93 ± 0.26
M1 DNA 1/12 27.8 ± 2.86 10.25 ± 0.35
NP+M1 DNAs 3/12 20.2 ± 0.54 8.96 ± 0.66
Unimmunized 0/12 26.1 ± 1.76 10.85 ± 0.21
Pre-exposed
to H1N1
NP DNA 10/12
a, b 8.5 ± 2.01
a, b 6.43 ± 0.84
a, b
M1 DNA 4/12 20.1 ± 2.63
a, 10.05 ± 0.07
NP+M1 DNAs 12/12
a, b 7.9 ± 0.72
a, b 7.12 ± 0.17
a, b
Unimmunized 4/12
a 17.8 ± 1.29
a 9.78 ± 1.39
§Mice were randomized into two groups. One group was infected with H1N1 virus, and the other was uninfected. Six weeks later, mice in each group were
randomly divided into 4 subgroups. Three subgroups were immunized with a single dose of NP DNA, M1 DNA and NP+M1 DNAs, respectively, and the rest
remained unimmunized as a control. Six weeks after immunization, all the mice were challenged with a lethal dose (20LD50) of H5N1 virus. Lung virus titers,
body weight losses and survival rates of mice were determined 3 days, 7 days and 21 days post-challenge, respectively.
aSignificant difference (p < 0.05), compared with the corresponding unexposed mice.
bSignificant difference (p < 0.05), compared with the pre-exposed but unimmunized control.
*One mouse in the group died during anesthesia.
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immune responses. Due to antigenic drift that is a con-
tinuous ongoing process in type A influenza virus, the
immunity induced by a certain strain is usually limited.
However, more and more recent researches have
demonstrated that specific CTLs, established by influ-
enza exposure and mostly targeting the virus internal
proteins, provide some level of cross-protection against
not only antigenically distinct viruses of the same sub-
type (drift variants) but also different subtypes [10-13].
In vitro testing with T cells isolated from healthy volun-
teers has been proved that the T cells could cause host
cells infected with swine or avian influenza virus to
undergo lysis [7,8]. In vivo experiments using a mouse
model have also testified the cross-protection offered by
influenza T cell responses against lethal challenge with
heterologous virus [14,15]. Similar results were obtained
i no u rp r e s e n ts t u d y .A f t e re x p o s e dt oA / P R 8 ( H 1 N 1 )
virus, mice gained partial protection against lethal A/
chicken/Henan/12/2004(H5N1) virus challenge. Four of
the total 12 mice survived (Table 2). Transfer of anti-
H1N1 antiserum to naive mice could fully protect mice
against H1N1 virus challenge, but had no use in defend-
ing them against H5N1 virus challenge (Table 1). These
indicate that the partial intersubtypic cross-protection
mainly relies on the cell-mediated immune responses
induced by infection.
Though the cross-protection provided by infection
could play a role in alleviating symptoms of H5N1 infec-
tion and reducing death, it is after all very limited. Vac-
cination is an indispensable way to fight against human
infection with avian H5H1 virus. Various kinds of vac-
cines to H5N1 influenza virus have been tried preclini-
cally or clinically, including inactivated whole-virion
vaccines [16,17], split vaccines [18,19] and subunit vac-
cines [20]. However, these vaccines induce only humoral
responses and are mainly based on the virus surface
Figure 1 Body weight changes of mice post-challenge.M i c e
unexposed or pre-exposed to H1N1 virus were immunized with a
single dose of H5N1 virus NP (A), M1 (B) or NP + M1 DNAs (C),
respectively. Six weeks after immunization, all the mice were
challenged with a lethal dose (20LD50) of H5N1 virus. Body weights
of mice were recorded at 0, 3, 7, 10, 14, and 21 days after challenge.
Table 3 Specific Ab titers in unexposed and pre-exposed
mice after immunization
§
Ab titer by ELISA (log2)
Group Subgroup
(DNA vaccine)
Anti-NP Anti-M1
Unexposed
to H1N1
NP DNA 12.5 ± 1.0 Not done
M1 DNA Not done 10.0 ± 0.81
NP + M1 DNAs 12.5 ± 0.58 10.5 ± 1.29
Pre-exposed
to H1N1
NP DNA 22.0 ± 0.57
a, b Not done
M1 DNA Not done 12.7 ± 1.15
a, b
NP + M1 DNAs 22.3 ± 1.15
a, b 13.3 ± 0.57
a, b
Unimmunized control 17.0 ± 1.0 9.33 ± 0.57
§Mice were grouped and treated as described in Table 2. Three days after the
lethal H5N1 challenge, six mice from each subgroup were sacrificed for
specific IgG Ab detection by ELISA. NP and M1 proteins obtained by
prokaryotic expression were used to coat the microtiter plate. Values
represent means ± SD of each group.
aSignificant difference (p < 0.05), compared with the corresponding
unexposed mice.
bSignificant difference (p < 0.05), compared with the pre-exposed but
unimmunized control.
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and have been proved to be low immunogenic. Adjuvant
addition and increased dose of antigen have to be
adopted to increase the immune effect [21,22]. Com-
pared with these conventional vaccines, DNA vaccine
has lots of advantages. It induces balanced immune
responses and can be prepared in a short time and on a
large scale, with high purity and stability [23]. It seems
that DNA vaccine is a suitable candidate for pandemic
vaccines. According to our previous studies, influenza
DNA vaccines based on the surface protein, hemaggluti-
nin or neuraminidase, could provide good protection
against lethal challenge with homologous virus, includ-
ing H5 and other subtypes, whereas those based on the
internal protein, either NP or M1, failed to offer satis-
factory protection even with multi-dose injection
[24-27]. In our present study, after mice had been
infected beforehand with A/PR8 (H1N1) to mimic the
seasonal influenza virus infection, they were immunized
once with H5N1 virus NP DNA, M1 DNA or NP + M1
DNAs, and were then challenged with a lethal dose of
the homologous H5N1 virus. The results are somehow
unexpected (Table 2). The survival rates offered by a
single dose of H5N1 NP DNA or NP + M1 DNA vacci-
nation in pre-exposed mice reached 83% (10/12) and
100% (12/12), respectively. The protective ability (as
expressed by survival rate, bodyweight loss and lung
virus titer) in these two subgroups of mice had signifi-
cant difference as compared with that in pre-exposed
but unimmunized control group.
Influenza vaccines based on internal proteins induce
specific CTL responses that can kill infected cells and
help the host recovery from the infection. The antibo-
dies induced by NP or M1 contribute little to providing
protective ability, as shown in our and many other
researches [23,24,28,29]. In our present study, the level
of cellular immune responses, as reflected by the num-
ber of the IFN-g secreting splenocytes in mice, were cor-
related with degree of protection (Figure 2 and Table 2).
As i n g l ed o s eo fH 5 N 1N PD N Ao rN P+M 1D N A s
significantly enhanced the specific cellular response in
mice pre-exposed to H1N1 virus, compared with that in
the corresponding unexposed mice. In spite of this, we
noticed that, though the residue lung virus titers were
significantly reduced in pre-exposed mice immunized
with NP DNA or NP + M1 DNAs (Table 2), they were
Figure 2 IFN-g secreting splenocytes in unexposed and pre-exposed mice after immunization. BALB/c mice were randomized into two
groups, one infected with H1N1 virus and the other uninfected. Six weeks later, both groups were divided into 4 subgroups. Three of the
subgroups were immunized with H5 NP DNA, M1 DNA or NP + M1 DNAs, respectively, and the rest subgroup remained unimmunized.
Splenocytes of mice were isolated 6 weeks after immunization and stimulated by the synthesized NP or M1 peptide. The number of IFN-g
secreting splenocytes was calculated as the average number of spots in the triplicate stimulant wells. Abscissa description: NP + M1 (NP):
immunization with NP + M1 DNAs and stimulation with NP peptide; NP + M1 (M1): immunization with NP + M1 DNAs and stimulation with M1
peptide; NP: immunization with NP DNA and stimulation with NP peptide; M1: immunization with M1 DNA and stimulation with M1 peptide; C
(NP): unimmunization control and stimulation with NP peptide; C (M1): unimmunization control and stimulation with M1 peptide.
a Significant
difference (p < 0.05), compared with the corresponding unexposed mice.
b Significant difference (p < 0.05), compared with the pre-exposed but
unimmunized control.
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DNA, as shown in our previous experiments [9]. This
may be due to the lack of effective specific Abs to pre-
vent virus from attaching to and releasing among host
cells.
The concern about safety of DNA vaccines always
exists, including potential integration of plasmid into
host genome, induction of autoimmune responses or
immunologic tolerance, and so on, but DNA vaccines
have been approved to use in animals such as horses
[30] and dogs [31]. DNA vaccines have also entered the
clinic for initial safety and immunogenicity testing in
humans for various infectious diseases, like HIV infec-
tions [32], influenza virus infections [33], malaria [34]
and hepatitis B infections [35]. All DNA vaccines tested
so far were well tolerated with no local or systemic ser-
ious adverse effects [36].
Conclusions
The present study shows that pre-existing immunity
against seasonal influenza viruses is useful in offering
protection against H5N1 infection, as has been demon-
strated before [14]. It also suggests that DNA vaccina-
tion may be at least a good choice for individuals
innaive to influenza A virus during H5N1 pandemic
while strain-matched vaccines are being prepared. Inter-
nal protein genes are highly conserved among all influ-
enza A viruses [37]. Whether H5 DNA vaccines
encoding the proteins can provide intrasubtypic or even
intersubtypic cross-protection in the host pre-exposed
to influenza A virus needs to be investigated further.
Methods
Viruses and mice
Influenza virus strains used in this study included a
mouse-adapted A/PR/8/34(H1N1) virus and an H5N1
virus A/chicken/Henan/12/2004(H5N1), which had been
through repeated lung-to-lung passages and adapted in
mice as described in our previous studies [25,38]. They
were frozen at -70°C until use. All the experiments with
live H5N1 virus were performed in a biosafety level 3
containment facilities. SPF female BALB/c mice, aged 6-
8 weeks old, were purchased from the Center for Dis-
ease Control and Prevention in Hubei Province, China.
They were bred and maintained in SPF conditions all
along. All the performances on mice in this study fol-
lowed the Chinese Regulations for the Administration of
Laboratory Animals.
DNA vaccines and peptides
Plasmids pCAGGSP7/NP, pCAGGSP7/M1 were con-
structed by cloning the PCR products of NP and M1
genes from the A/chicken/Henan/12/2004(H5N1) influ-
enza virus strain into the plasmid expression vector
pCAGGSP7, respectively, as described previously [9,24].
The plasmids were propagated in E. coli XL1-blue bac-
teria and purified using QIAGEN purification kits (QIA-
GEN-tip 500). The peptide RAVKLYKKLKRE for M1
protein [39] and the peptide TYQRTRALV for NP pro-
tein [40], which were used for IFN-g ELISPOT assay,
were synthesized by Shanghai Sangon Biological Engi-
neering Technology & Services Co., Ltd, China.
Virus infection and challenge
The virus pre-exposure mouse model was achieved by
intranasal infection with 5 μl of the viral suspension con-
taining 5LD50 influenza virus A/PR/8/34 six weeks before
immunization. For challenge experiments, the mice were
anesthetized and challenged with 20 μlo ft h ev i r a ls u s -
pension containing 20LD50 influenza virus A/chicken/
Henan/12/2004(H5N1) or A/PR8(H1N1) by intranasal
route. The small volume of the virus suspension induced
local infection, which was not lethal. On the other hand,
the large volume induced total respiratory infection that
caused virus shedding from the lung and led to death
from viral pneumonia 5 - 10 days later [41].
Immunization
Mice were immunized with NP DNA, M1 DNA or a
mixture of the two DNAs dissolved in 50 μlo fT r i s -
EDTA buffer at a dosage of 50 μg( 2 5μge a c hi nt h e
mixture of two DNAs) by injection into the quadriceps
muscles. After injection, a pair of electrode needles with
5 mm apart was inserted into the muscle to cover the
DNA injection site and electric pulses were delivered
using an electric pulse generator (Electro Square Porator
T 8 3 0M ;B T X ,S a nD i e g o ,C A ) .T h r e ep u l s e so f1 0 0V
each, followed by three pulses of the opposite polarity,
were delivered to each injection site at a rate of one
pulse per second. Each pulse lasted for 50 ms.
Specimens
Three days after the challenge, six mice from each
group were randomly taken out for sample collection.
The mice were anaesthetized with chloroform and then
bled from the heart with a syringe. The sera were col-
lected from the blood and used for specific IgG Ab
a s s a y .A f t e rb l e e d i n g ,t h em i c ew e r ei n c i s e dv e n t r a l l y
along the median line from the xiphoid process to the
point of the chin. The trachea and lungs were taken out
and washed 3 times by injecting with a total of 2 ml of
PBS containing 0.1% BSA. The bronchoalveolar washes
were used for virus titration after removing cellular deb-
ris by centrifugation.
Ab assay by ELISA
The concentrations of IgG Abs against H1N1 virus, NP
or M1 protein were measured by ELISA. ELISA was
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ies of reagents consisting of first, inactivated H1N1 vac-
cine, NP or M1 protein prepared by Shanghai Institute
of Biological Products; second, serial 2-fold dilutions of
sera from each group of immunized or preimmunized
mice; third, goat anti-mouse IgG Ab (g-chain specific)
(Southern Biotechnology Associates) conjugated with
biotin; fourth, streptavidin conjugated with alkaline
phosphatase (Southern Biotechnology Associates); and
finally, p-nitrophenyl-phosphate. The amount of chro-
mogen produced was measured based on absorbance at
405 - 450 nm in an ELISA reader (Labsystems Multis-
kan Ascent). Ab-positive cut-off values were set as
means + 2 × SD of preimmunized sera. An ELISA Ab
titer was expressed as the highest serum dilution giving
a positive reaction.
HI assay
The anti-HA Ab titers were measured by HI assay.
Receptor destroying enzyme-treated sera were serially
diluted (twofold) in V-shaped 96-well plates. Four
hemagglutination units of virus were added to the test
and incubated at room temperature for 15 min, followed
by addition of 0.5% red blood cells and incubation at
room temperature for 30 min. The HI titer is the reci-
procal of the highest serum dilution that completely
inhibits hemagglutination.
Passive serum transfer
Naive mice were passively immunized by tail vein injec-
tion with 300 μl of pooled serum from mice infected
with A/PR8 (H1N1) influenza virus six weeks before or
from mice uninfected. One day after the serum transfer,
mice were challenged, as described above, with 20LD50
of H5N1 or H1N1 influenza virus.
IFN-g ELISPOT assay
Spleen cells were isolated from mice for ELISPOT
assays at 6 weeks after the vaccination. According to the
instruction manual (U-CyTech, Netherlands), 96-well
PVDF plates (Millipore, Bedford, MA) were coated with
100 μlo f1 0μg/ml rat anti-mouse IFN-g Ab in PBS and
incubated at 4°C overnight. The plates were washed 3
times with sterile PBS and then blocked with 200 μlo f
blocking solution R and incubated at 37°C for 1 h. Next,
1×1 0
5 lymphocytes isolated from the spleen cells were
added to the wells in triplicate, stimulated with 2 μg/ml
of a synthesized influenza virus peptide, and incubated
at 37°C for 18 h. The lymphocytes were then removed,
and 100 μl of biotinylated anti-mouse IFN-g Ab was
added to each well and incubated at 37°C for 1 h. Sub-
sequently, 100 μl of properly diluted Streptavidin-HRP
conjugate solution was added and incubated at room
temperature for 2 h after washing 5 times with PBS.
Finally, the plates were treated with 100 μlo fA E Cs u b -
strate solution and incubated at room temperature for
20 min in the dark. The reaction was stopped by wash-
ing with dematerialized water. The plates were air-dried
at room temperature and read using an ELISPOT reader
(Bioreader 4000; Bio-sys, Germany).
Virus titrations
To examine cytopathic effect, the bronchoalveolar
washes, diluted 10-fold serially starting from a dilution
of 1:10, were inoculated onto the MDCK cells at 37°C
for 2 days. The virus titer of each specimen, expressed
as TCID50, was calculated by the Reed-Muench method.
The virus titer in each experimental group was repre-
sented by the mean ± SD of the virus titer per ml of
specimens from six mice in each group.
Statistics
The data from test groups were evaluated by Student’s
t-test; if P-value was less than 0.05, the difference was
considered significant. The survival rates of mice in test
and control groups were compared by using Fisher’s
exact test.
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